409 533

Cited 0 times in

CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel

DC Field Value Language
dc.contributor.author남효석-
dc.contributor.author이경열-
dc.contributor.author한상원-
dc.date.accessioned2020-02-11T06:07:10Z-
dc.date.available2020-02-11T06:07:10Z-
dc.date.issued2019-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/174542-
dc.description.abstractBackground: The “comparison of triflusal and clopidogrel effects in secondary prevention of stroke based on cytochrome P450 2C19 (CYP2C19) genotyping (MAESTRO)” study was a prospective, multicenter, randomized, open-label, and blind genotype trial. We performed a subgroup analysis of the MAESTRO study to explore the relationship between VerifyNow P2Y12 assay with regard to CYP2C19 polymorphisms and smoking status in patients with non-cardiogenic ischemic stroke who underwent clopidogrel treatment. Methods: For the study, patients treated with clopidogrel and who underwent VerifyNow P2Y12 assay was selected from the MAESTRO study. Results: Of the 393 patients in 18 hospitals, 256 (65%) patients in 12 hospitals were entered for this subgroup analysis. P2Y12 reaction unit (PRU) was significantly lower and percent inhibition (% INH) was higher in the current smoking group than in the nonsmoking group (p<0.001). The same results were also observed in the good genotype group when compared with the poor genotype group (p<0.001). Among the groups, significant lower PRU and higher % INH was demonstrated in current smoking with good genotype group. However, there was no difference in PRU and % INH between current smoking with poor genotype group and nonsmoking with good genotype group, suggesting that clopidogrel activity was concurrently related to CYP2C19 polymorphisms and smoking status. Conclusions: Regarding secondary stroke prevention, patients who were current smokers and had a poor genotype for clopidogrel metabolism may benefit from clopidogrel treatment similar to that in patients who were nonsmokers and had a good genotype.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Society of Cardiovascular Disease Prevention-
dc.relation.isPartOfCardiovascular Prevention and Pharmacotherapy-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학교실)-
dc.contributor.googleauthorSang Won Han-
dc.contributor.googleauthorYong-Jae Kim-
dc.contributor.googleauthorWoo-Keun Seo-
dc.contributor.googleauthorSungwook Yu-
dc.contributor.googleauthorHyo Suk Nam-
dc.contributor.googleauthorSung Sang Yoon-
dc.contributor.googleauthorSeo Hyun Kim-
dc.contributor.googleauthorJong Yun Lee-
dc.contributor.googleauthorJun Hong Lee-
dc.contributor.googleauthorYang-Ha Hwang-
dc.contributor.googleauthorJun Lee-
dc.contributor.googleauthorKyung-A Lee-
dc.contributor.googleauthorKyung-Yul Lee-
dc.identifier.doi10.36011/cpp.2019.1.e8-
dc.contributor.localIdA01273-
dc.contributor.localIdA02648-
dc.contributor.localIdA04285-
dc.relation.journalcodeJ03760-
dc.identifier.eissn2671-700X-
dc.subject.keywordClopidogrel-
dc.subject.keywordPolymorphism, genetic-
dc.subject.keywordPolymorphism, Single nucleotide-
dc.subject.keywordSmoking-
dc.subject.keywordStroke-
dc.contributor.alternativeNameNam, Hyo Suk-
dc.contributor.affiliatedAuthor남효석-
dc.contributor.affiliatedAuthor이경열-
dc.contributor.affiliatedAuthor한상원-
dc.citation.volume1-
dc.citation.number2-
dc.citation.startPage63-
dc.citation.endPage70-
dc.identifier.bibliographicCitationCardiovascular Prevention and Pharmacotherapy, Vol.1(2) : 63-70, 2019-
dc.identifier.rimsid64610-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.